Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Abstract Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the d...
Saved in:
Main Authors: | Yi Hu, Yuetao Xie, Xiaodong Wang, Lufeng Yang, He Geng, Zugang Yi, Yao Zhang, Lin Ma, Fang Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-02-01
|
Series: | Cancer Immunology, Immunotherapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00262-024-03913-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
by: P. Joy Ho, et al.
Published: (2025-01-01) -
CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies
by: Fang Wang, et al.
Published: (2025-02-01) -
Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01) -
Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2025-01-01) -
Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints
by: Bastian Engel, et al.
Published: (2025-02-01)